Gilead signs royalty-free generic licensing deals for its experimental Ebola drug in 127 countries
Gilead Sciences said on Monday it has signed royalty-free voluntary licensing agreements with three generic manufacturers — Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories — to support future access to obeldesivir, its experimental antiviral being tested as post-exposure prevention for Ebola Bundibugyo virus disease. The deals cover 127 mainly low- and lower-middle-income countries, including every African country that has reported cases in the current outbreak. The drug is not approved anywhere, and a Phase 3 trial is still under way.

Key points
- Three generic makers — Dr. Reddy's, Eva Pharma and Ferozsons — can prepare to make obeldesivir royalty-free in 127 countries.
- The territory includes every African country reporting cases in the current Ebola Bundibugyo outbreak.
- Obeldesivir is experimental: a Phase 3 post-exposure trial is still running and it is approved nowhere.
Show more (1)
- Gilead is also extending its remdesivir licences to filovirus disease, conditional on trial results and approvals.
What happened
The current Ebola outbreak, driven by the Bundibugyo species, was announced in DR Congo in mid-May and has become the country's largest, with cases also reported in other African countries. There is no approved vaccine or specific treatment for the Bundibugyo virus, which is why prevention after exposure is being tested in the field.
Licensing generic makers before a drug is approved is meant to shorten the gap between a successful trial and affordable supply in the countries where the disease occurs.
What we know / what we don't know yet
What we know
- The three licensees, the royalty-free terms and the 127-country scope, from Gilead's own announcement.
- That obeldesivir is unapproved everywhere and still in a Phase 3 post-exposure trial.
What we don't know yet
- Whether the EBO-PEP trial shows obeldesivir prevents Ebola Bundibugyo disease — no results have been announced.
- Whether regulators approve the drug, and when generic supply could reach patients if they do.
Claim by claim
Show all claims (4)
Why this label: The agreements, the three manufacturers and the 127-country scope are set out in Gilead's own announcement; Reuters' report of the deals agrees.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The trial's design and the drug's unapproved status are stated in Gilead's announcement and in Reuters' report; no efficacy result has been announced.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The purpose and the state of the technology-transfer talks are Gilead's own account in its announcement.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The remdesivir licence update and its conditions are stated in Gilead's announcement; the PARTNERS trial has not reported.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why it matters
If obeldesivir works, the deals decide how fast and how cheaply it can reach the African countries fighting this outbreak — the manufacturing and supply groundwork is being laid now, before anyone knows whether the drug succeeds.
Background
The Ebola Bundibugyo outbreak was announced in DR Congo; it has become the country's largest Ebola outbreak.
Gilead signed royalty-free licensing deals with three generic manufacturers for obeldesivir, covering 127 countries.
Update history
No silent edits. Every change is written here, with its time.
- Latest
Published — the deals are confirmed against Gilead's own announcement, with Reuters reporting them in the same terms.